FTO deficiency in older livers exacerbates ferroptosis during ischaemia/reperfusion injury by upregulating ACSL4 and TFRC
-
Published:2024-06-04
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Li RongORCID, Yan Xijing, Xiao Cuicui, Wang Tingting, Li XuejiaoORCID, Hu Zhongying, Liang JinliangORCID, Zhang Jiebin, Cai Jianye, Sui Xin, Liu Qiuli, Wu Manli, Xiao JiaqiORCID, Chen HaitianORCID, Liu YasongORCID, Jiang Chenhao, Lv Guo, Chen Guihua, Zhang Yingcai, Yao JiaORCID, Zheng JunORCID, Yang Yang
Abstract
AbstractOlder livers are more prone to hepatic ischaemia/reperfusion injury (HIRI), which severely limits their utilization in liver transplantation. The potential mechanism remains unclear. Here, we demonstrate older livers exhibit increased ferroptosis during HIRI. Inhibiting ferroptosis significantly attenuates older HIRI phenotypes. Mass spectrometry reveals that fat mass and obesity-associated gene (FTO) expression is downregulated in older livers, especially during HIRI. Overexpressing FTO improves older HIRI phenotypes by inhibiting ferroptosis. Mechanistically, acyl-CoA synthetase long chain family 4 (ACSL4) and transferrin receptor protein 1 (TFRC), two key positive contributors to ferroptosis, are FTO targets. For ameliorative effect, FTO requires the inhibition of Acsl4 and Tfrc mRNA stability in a m6A-dependent manner. Furthermore, we demonstrate nicotinamide mononucleotide can upregulate FTO demethylase activity, suppressing ferroptosis and decreasing older HIRI. Collectively, these findings reveal an FTO-ACSL4/TFRC regulatory pathway that contributes to the pathogenesis of older HIRI, providing insight into the clinical translation of strategies related to the demethylase activity of FTO to improve graft function after older donor liver transplantation.
Publisher
Springer Science and Business Media LLC
Reference56 articles.
1. Dickson, K. M. & Martins, P. N. Implications of liver donor age on ischemia reperfusion injury and clinical outcomes. Transplant. Rev. 34, 100549 (2020). 2. Durand, F. et al. Age and liver transplantation. J. Hepatol. 70, 745–758 (2019). 3. Chen, X., Kang, R., Kroemer, G. & Tang, D. Ferroptosis in infection, inflammation, and immunity. J. Exp. Med. 218, e20210518 (2021). 4. Meng, Y. et al. BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition. Mil. Med. Res. 10, 61 (2023). 5. Chen, J., Li, X., Ge, C., Min, J. & Wang, F. The multifaceted role of ferroptosis in liver disease. Cell Death Differ. 29, 467–480 (2022).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|